Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study

NCT00571649 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00571649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00571649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
November 30, 2010
Enrollment
8,101 (actual)
Sites
676

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism